142 related articles for article (PubMed ID: 24992955)
1. Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.
Barau C; Braun J; Vincent C; Haim-Boukobza S; Molina JM; Miailhes P; Fournier I; Aboulker JP; Vittecoq D; Duclos-Vallée JC; Taburet AM; Teicher E;
Clin Infect Dis; 2014 Oct; 59(8):1177-84. PubMed ID: 24992955
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
Gantner P; Koeppel C; Partisani M; Batard ML; Bernard-Henry C; Cheneau C; De Mautort E; Priester M; Muret P; Sueur C; Fafi-Kremer S; Rey D
Scand J Infect Dis; 2014 Dec; 46(12):838-45. PubMed ID: 25229167
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults.
Carey D; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray JE; Boyd MA; Emery S; Cooper DA
J Acquir Immune Defic Syndr; 2012 Jun; 60(2):143-9. PubMed ID: 22421745
[TBL] [Abstract][Full Text] [Related]
5. Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial.
Matignon M; Lelièvre JD; Lahiani A; Abbassi K; Desvaux D; Diallo A; Peraldi MN; Taburet AM; Saillard J; Delaugerre C; Costagliola D; Assoumou L; Grimbert P;
HIV Med; 2019 Mar; 20(3):202-213. PubMed ID: 30688008
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients.
Casado JL; Bañón S; Rodriguez MA; Moreno A; Moreno S
Antiviral Res; 2015 Jan; 113():103-6. PubMed ID: 25460844
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients.
Jansen A; Colbers EP; van der Ven AJ; Richter C; Rockstroh JK; Wasmuth JC; van Luin M; Burger DM
HIV Med; 2013 Aug; 14(7):449-52. PubMed ID: 23506243
[TBL] [Abstract][Full Text] [Related]
8. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
9. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
Baroncelli S; Villani P; Weimer LE; Ladisa N; Francisci D; Tommasi C; Vullo V; Preziosi R; Cicalini S; Cusato M; Galluzzo C; Floridia M; Regazzi M;
Ann Pharmacother; 2010 May; 44(5):838-43. PubMed ID: 20371753
[TBL] [Abstract][Full Text] [Related]
10. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects.
Cattaneo D; Gervasoni C; Meraviglia P; Landonio S; Fucile S; Cozzi V; Baldelli S; Pellegrini M; Galli M; Clementi E
J Antimicrob Chemother; 2012 Feb; 67(2):460-4. PubMed ID: 22127581
[TBL] [Abstract][Full Text] [Related]
11. Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
Fayet Mello A; Buclin T; Franc C; Colombo S; Cruchon S; Guignard N; Biollaz J; Telenti A; Decosterd LA; Cavassini M
J Antimicrob Chemother; 2011 Jul; 66(7):1573-81. PubMed ID: 21508009
[TBL] [Abstract][Full Text] [Related]
12. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Conti F; Clementi E
Ther Drug Monit; 2010 Dec; 32(6):782-6. PubMed ID: 20926993
[TBL] [Abstract][Full Text] [Related]
13. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
[TBL] [Abstract][Full Text] [Related]
14. Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.
Lê MP; Valantin MA; Assoumou L; Soulie C; Le Mestre S; Weiss L; Yazdanpanah Y; Molina JM; Bouchaud O; Raffi F; Reynes J; Calvez V; Marcelin AG; Costagliola D; Katlama C; Peytavin G;
Pharmacotherapy; 2019 Apr; 39(4):514-520. PubMed ID: 30815916
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
Fabbiani M; Mondi A; Colafigli M; D'Ettorre G; Paoletti F; D'Avino A; Ciccarelli N; Sidella L; Murri R; Fortuna S; Vullo V; Cauda R; De Luca A; Di Giambenedetto S
Scand J Infect Dis; 2014 Jan; 46(1):34-45. PubMed ID: 24161018
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.
Vera JH; Jackson A; Dickinson L; Else L; Barber T; Mora-Peris B; Back D; Boffito M; Winston A
HIV Clin Trials; 2015; 16(1):39-42. PubMed ID: 25777188
[TBL] [Abstract][Full Text] [Related]
17. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.
McAllister J; Read P; McNulty A; Tong WW; Ingersoll A; Carr A
HIV Med; 2014 Jan; 15(1):13-22. PubMed ID: 24007390
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs.
Tricot L; Teicher E; Peytavin G; Zucman D; Conti F; Calmus Y; Barrou B; Duvivier C; Fontaine C; Welker Y; Billy C; de Truchis P; Delahousse M; Vittecoq D; Salmon-Céron D
Am J Transplant; 2009 Aug; 9(8):1946-52. PubMed ID: 19519819
[TBL] [Abstract][Full Text] [Related]
19. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
20. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Reliquet V; Chirouze C; Allavena C; Muret P; Peytavin G; André-Garnier E; Bettinger D; Ferré V; Hoen B; Raffi F
Antivir Ther; 2014; 19(1):117-23. PubMed ID: 24145365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]